Operating CF
$1.89B
Capex
−$135.74M
Free Cash Flow
$1.75B
FCF Margin
+92.8%
Cash flow waterfall for ResMed (RMD) — TTM through Q1 2026
Free cash flow: $1.75B
Cash flow breakdown for ResMed (RMD) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $1.89B | $1.89B |
| Capital Expenditure | −$135.74M | $1.75B |
| Free Cash Flow | $1.75B | $1.75B |
| Acquisitions | −$163.98M | $1.59B |
| Other Investing | $4.46M | $1.59B |
| Share Buybacks | −$600.04M | $994.66M |
| Dividends Paid | −$340.16M | $654.50M |
| Other Financing | $32.45M | $686.95M |
| Forex Effect | $40.85M | $727.80M |
| Net Cash Increase | $727.80M | $727.80M |
- Operating Cash Flow$1.89B
- Capital Expenditure−$135.74M
- Free Cash Flow$1.75B
- Acquisitions−$163.98M
- Other Investing$4.46M
- Share Buybacks−$600.04M
- Dividends Paid−$340.16M
- Other Financing$32.45M
- Forex Effect$40.85M
- Net Cash Increase$727.80M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
ResMed (RMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement